Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data

被引：0
|
作者：
L. Cui
T. He
Y. Jiang
M. Li
O. Wang
R. Jiajue
Y. Chi
Q. Xu
X. Xing
W. Xia
机构：
[1] Chinese Academy of Medical Sciences,Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital
[2] Chinese Academy of Medical Sciences,Department of Hematology, Peking Union Medical College Hospital
[3] Beijing Jishuitan Hospital,Department of Orthopedics
来源：
Osteoporosis International | 2020年 / 31卷
关键词：
Chinese; cost-effectiveness; FRAX; Markov; osteoporosis; zoledronate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：307 / 316
页数：9
相关论文
共 50 条
  • [41] Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study
    E. C.-C. Lai
    T.-C. Lin
    J. L. Lange
    L. Chen
    I. C. K. Wong
    C.-W. Sing
    C.-L. Cheung
    S.-C. Shao
    Y.-H. Kao Yang
    Osteoporosis International, 2022, 33 : 1155 - 1164
  • [42] Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women
    M. Chandran
    G. Ganesan
    K.B. Tan
    J.-Y. Reginster
    M. Hiligsmann
    Osteoporosis International, 2021, 32 : 133 - 144
  • [43] Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis
    Sicras-Mainar, Antoni
    Sorio-Vilela, Francesc
    Sacrest-Soy, Marta
    Gatell, Sonia
    Sicras-Navarro, Aram
    Villoro-Valdes, Renata
    Rebollo-Gomez, Elena
    Hernandez, Ignacio
    RHEUMATOLOGY AND THERAPY, 2025, 12 (02) : 315 - 335
  • [44] COST-EFFECTIVENESS OF FRAX®-BASED INTERVENTION THRESHOLDS FOR MANAGEMENT OF OSTEOPOROSIS IN INDIAN WOMEN
    Nagendra, L.
    Chandran, M.
    Bhattacharya, S.
    Reginster, J-Y
    Hiligsmann, M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S376 - S376
  • [45] COST-EFFECTIVENESS OF FRAX® BASED INTERVENTION THRESHOLDS FOR MANAGEMENT OF OSTEOPOROSIS IN SINGAPOREAN WOMEN
    Chandran, M.
    Ganesan, G.
    Tan, K. B.
    Reginster, J. Y.
    Yong, E. L.
    Hiligsmann, M.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S459 - S459
  • [46] Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women
    Chandran, M.
    Ganesan, G.
    Tan, K. B.
    Reginster, J-Y
    Hiligsmann, M.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (01) : 133 - 144
  • [47] Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study
    Gold, Deborah T.
    Beckett, Tammy
    Deal, Chad
    James, Andrew L.
    Mohseni, Mahshid
    Mcmillan, Abigail
    Bailey, Tom
    Pearman, Leny
    Caminis, John
    Wang, Yamei
    Williams, Setareh A.
    Kernaghan, Jacqueline M.
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (08) : 1407 - 1415
  • [48] Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
    Barr, Heather K.
    Guggenbickler, Andrea M.
    Hoch, Jeffrey S.
    Dewa, Carolyn S.
    CURRENT ONCOLOGY, 2023, 30 (04) : 4078 - 4093
  • [49] THE EFFECT OF THE DRUG LIFE CYCLE PRICE ON COST-EFFECTIVENESS RESULTS: A REAL-WORLD DATA ANALYSIS
    Schottler, M.
    Coerts, F.
    Postma, M.
    Boersma, C.
    Rozenbaum, M.
    VALUE IN HEALTH, 2022, 25 (01) : S109 - S109
  • [50] Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis
    Solomon, DH
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : 1967 - 1975
12345